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ABSTRACT

Huntington disease (HD) is a devastating and fatal neurodegenerative disease. At the
moment, no disease modifying therapies are available, with only symptomatic treatment offered
to alleviate psychiatric and some types of motor deficits. As a result, many people will continue
to suffer and die from this disease. Small molecule therapies have failed to provide benefit in
HD, necessitating more complex gene therapy approaches and the identification of less
traditional therapeutic targets. A previous study demonstrated that preventing cleavage of the
huntingtin (HTT) protein, the protein that when mutated causes HD, by caspase 6 (C6) at amino
acid 586 prevents the onset of disease in transgenic HD model mice. This suggests that inhibiting
the toxicity initiated by N586 cleavage could be a promising therapeutic strategy, but a safe and
specific way to do this in humans has not been identified. General C6 inhibition is not a feasible
strategy due to the vital functions it plays throughout life. Thus, the purpose of this study was to
investigate whether the C6 cleavage fragment of HTT, N586, is itself a toxic species of HTT or if
it initiates a toxic proteolytic pathway in order to identify more viable therapeutic strategies for
HD. To accomplish this, we are using novel and highly sensitive immunoprecipitation and flow
cytometry (IP-FCM) protein detection assays, specific for the N586 neoepitope of HTT, to
evaluate the in vivo persistence of N586 in HD model mice. If N586 is detected, it is likely that it
is itself toxic and promoting its degradation may be beneficial. Conversely, if it is not detected,
N586 cleavage likely initiates a toxic degradation pathway and promoting its stability may be
beneficial.
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The results of these studies have the potential to define new therapeutic strategies for HD
that can be addressed more specifically than generalized C6 inhibition for the prevention of
N586-mediated toxicity. The selective targeting of N586 toxicity, either to promote or prevent its
degradation depending on our results, would ensure that therapeutic activity is restricted to HTT
and reduce the potential for deleterious off-target effects
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CHAPTER I. INTRODUCTION

Huntington Disease (HD) is an autosomal dominant neurodegenerative disease caused by a
mutation in the short arm of chromosome 4 that codes for an expanded CAG repeat in exon 1 of
the huntingtin (HTT) gene1. Normal individuals can have CAG repeat sizes anywhere from 9-24,
whereas individuals with HD will have CAG repeats greater than 35, with reduced penetrance
from 36 to 392. Furthermore, juvenile onset occurs in individuals with repeats greater than 603.
This expanded CAG repeat results in the translation of an abnormally long mutant HTT (mtHTT)
protein that interferes with many cellular pathways, resulting in cell degeneration and death. The
brain regions most affected in HD are the basal ganglia4, including the caudate nucleus and the
putamen, which are largely responsible for voluntary motor control, in addition to motor
learning, executive functions, behavior, and emotions5. Other areas of degeneration include the
cortex6,7 and white matter8.
Individuals with HD exhibit motor dysfunction such as loss of fine motor control, motor
impersistence, gait abnormalities, and uncontrollable movements known as chorea, as well as
cognitive and psychiatric deficits including memory loss, anxiety, and depression9. HD is
incurable and fatal, resulting in death typically 15-20 years after onset10, and is extremely
debilitating for patients and their loved ones. At the moment, there are no disease-modifying
treatments for HD, only moderately beneficial symptomatic treatments, such as antidepressants
for depression and tetrabenazine for chorea11.
Traditional small molecule approaches to the treatment of HD have failed, likely due to the
complexity of the protein and the disease pathogenesis. HD is a multifaceted disease in which
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many molecules and cellular processes are perturbed. The reason being that HTT is an incredibly
large and promiscuous protein playing a role in multiple cellular pathways and having many
binding partners within the cell. Major functions of HTT include transcriptional regulation,
regulation of energy production, vesicle transport, protein homeostasis, synaptic function, stress
response signaling, scaffolding, autophagosome cargo recognition, and NMDAR regulation12,13.
It has many binding partners, including proteins, nucleic acids, and organelles13,14. The
promiscuity and diverse functions of HTT and the resulting wide range of cellular processes
perturbed by mtHTT are likely the reason that traditional small molecule therapeutic approaches,
which typically target a single pathologic process, have failed.
For instance, the largest ever study in HD patients sought to improve mitochondrial function
and reduce oxidative stress by coenzyme Q10 (CoQ10) treatment. CoQ10 is an enzyme that
plays a role in oxidative phosphorylation and acts as an antioxidant, but the trial was halted early
for futility15. Other failed therapeutic approaches targeting single molecules and pathways
include the CREST-E study, which focused on improving impaired energy production by
providing creatinine supplements16, a high energy phosphate source for restoring adenosine
triphosphate (ATP), and the Amaryllis trail, which focused on facilitating neuronal
communication and signaling through inhibition of phosphodiesterase-1017, a regulator for both
cAMP and cGMP signaling cascades18.The failure of these therapeutic approaches is likely due
to targeting single pathologic processes, when in reality there are so many processes and
pathways affected by HD that treating one or a few is ineffective, leaving a multitude unchanged.
Thus, therapeutic approaches that modulate mtHTT, the direct cause of the disease, have a
greater likelihood of success.
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A previous study demonstrated that preventing cleavage at the amino acid 586 caspase-6
(C6) cleavage site of HTT prevents the onset of disease in a transgenic mouse model of HD,
YAC128. YAC128 mice carry a full-length human mtHTT transgene and display a wide variety
of HD-like characteristics such as anxiety and depressive-like behavior, cognitive deficits, and
progressive motor deficits. Additionally, these mice undergo selective striatal
neurodegeneration19,20. A companion line, C6R, was created with a mutation in the C6 cleavage
site located in exon 13; thus, expressing an identical mtHTT transgene that cannot be cleaved by
C6. C6R mice express similar amounts of mtHTT as YAC128 mice and display widespread HTT
aggregation in the brain. However, C6R mice are completely protected from mtHTT toxicity,
and do not display any of the HD-like behavioral or neuropathological changes observed in
YAC128 mice, indicating protection from disease. These data suggest that N586 cleavage of
HTT is a rate-limiting step in HD pathogenesis and that inhibiting the subsequent toxicity may
be a promising therapeutic strategy for HD.
Inhibiting N586-linked toxicity by systemic inhibition of C6 is a non-specific and
potentially deleterious strategy considering that C6 activity has vital function throughout life. For
instance, in adults the region with highest C6 expression is the colon, where it likely plays a
critical role in ongoing apoptosis. Supporting this is the finding that the active form of C6 is
reduced in colon cancer21. Thus, systemic C6 inhibition may promote colon cancer. Therefore, a
more specific therapeutic strategy, addressing only the HTT N586 cleavage event, would be
preferable. HTT is processed through a variety of proteolytic events and pathways22, and Nterminal cleavage fragments of mtHTT likely play a predominant role in HD pathogenesis.
Supporting this is the earlier onset and greater severity of HD-like signs in transgenic mouse

3

models of HD expressing an N-terminal mtHTT fragment as compared to full-length mtHTT
models23. Thus, by investigating the location and quantity of N586 in the brains of HD mice and
in their biofluids, we hope to infer a possible role of N586 in HD pathogenesis, whether it be the
direct toxicity of the fragment itself or the toxicity of its degradation pathway.
Because N586 is only 1 of many species of mtHTT, a highly sensitive method would
likely be required to quantify it, even in brain tissue, where HTT protein is abundant24.
Immunoprecipitation and flow cytometry (IP-FCM) is a highly sensitive method of protein
detection that our lab has adapted to quantify mtHTT in HD patient and mouse cerebrospinal
fluid (CSF)25,26, where HTT protein is extremely low abundance (Figure 1). IP-FCM is highly
sensitive at detecting extremely low mtHTT concentrations in biofluids with up to femtomolar
detection (Figure 2). In order to develop an N586-specific IP-FCM assay to investigate the in
vivo persistence of N586, our lab screened anti-HTT antibody combinations including one or
both of a pair of N586 neoepitope-specific antibodies previously generated by Michael Hayden’s
laboratory at the University of British Columbia27.
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Figure 1. Schematic of detection of mHTT in CSF by immunoprecipitation and ﬂow
cytometry28 CML latex beads coupled to capture antibody were bound to mtHTT in the CSF of
HD patients or controls. Fluorophore conjugated probe Ab was then bound to the protein.
Relative concentration of mtHTT was measured using a flow cytometer to measure the
fluorescence intensity of the beads. Bead count vs fluorescence intensity is shown with the
control CSF in black and the HD CSF in red.
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a)

b)

Figure 2. Demonstration of IP-FCM sensitivity and specificity. “(A) HTT-IP-FCM median
fluorescence intensity (MFI) using serial dilutions of recombinant HTT fusion protein with 15 or
65 Q in ACSF using HDB4/MW1. Dashed lines indicate the mean ± SEM of the no-protein
controls, showing assay background. (B) HTT IP-FCM in brain lysates from Hu97/18, Hu18/18,
conditional Htt KO, and wildtype mice using HDB4/MW1.”25 Taken together these results
indicate that IP-FCM is extremely sensitive up to 16 fM, as well as, specific in that it can detect
mtHTT from wt.
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In this study, we set out to characterize the specificity and sensitivity of the high affinity
antibody pairs identified in this screen for use in the detection of N586 in brain tissue and
biofluids of HD model mice with the goal of eventually using them to investigate the location
and quantity of N586 in HD mouse brain and biofluids. If we find that N586 persists in brain
tissue, it may be an indicator of its direct toxicity. Thus, as a therapeutic approach, it might be
desirable to promote degradation of the fragment. Alternatively, if N586 is not detected, this may
indicate that the cleavage event initiates a toxic proteolytic pathway. In which case, a possible
therapeutic strategy may be to stabilize N586. The results of this study could identify novel
therapeutic targets and strategies for the treatment of HD.
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CHAPTER II. RESULTS
IVLD/HD55 and IVLD/MW1 are the Highest Affinity N586 IP-FCM Antibody Pairs
Our lab previously conducted a screen for IP-FCM capture/probe pairs with high affinity
for N586. Six anti-HTT antibodies (Abs) were used in the screen; 2 specific for the N586
neoepitope (HD55 and IVLD)27 (Figure 3) and 4 specific for additional target sites i.e. the Nterminus (BKP1)29, an epitope near the C-terminus of N586 (2166)30, polyproline (MW7)31, and
expanded polyglutamine, (MW1)31. Only combinations including at least one of the N586
neoepitope antibodies were screened, resulting in 18 combinations (Figure 4). To determine total
amount of N586, we wanted Ab combinations to recognize both mt and wtN586, so
combinations were screened against cell lysates transfected with either wt N586-Q15 or mtN586Q68. Four combinations, 2166/HD55, IVLD/2166, IVLD/HD55, and HD55/IVLD, produced
strong signals for mu and wt N586; interestingly, there were some reservations about using
IVLD and HD55 in combination since both recognize the neoepitope which could have resulted
in competition between the two for binding. Nevertheless, due to HD55 being polyclonal and
IVLD monoclonal, they appear to work well together. In addition, the signal was shifted further
to the right with IVLD/HD55 than IVLD/2166, 2166/HD55, or HD55/IVLD, indicating a
slightly higher affinity and thus the best combination. To determine the amount of mtN586, we
looked for combinations including MW1 because of its preference for expanded polyglutamine.
In our previous screen, MW1 was shown to be a better probe than capture Ab25, and the same
was seen here, further narrowing the criteria. While both HD55/MW1 and IVLD/MW1 were
identified as high affinity combinations, the latter shows the expected preferential recognition of
mtN586. Additionally, using IVLD as the capture Ab in both combinations would allow us to
8

use two separate probes of the same IP, increasing comparative potential. As a result,
IVLD/HD55, and IVLD/MW1 were identified as the best highly sensitive pairs with
IVLD/HD55 predicted to recognize both wt and mtN586, while IVLD/MW1 is predicted to
preferentially recognize mtN586.
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Figure 3. The neo-htt586 antibody specifically detects huntingtin 586 amino acid
fragments. “(C) Description of the three neo-epitope antibodies used in this study, including the
peptides used to generate the antibodies (caspase recognition sequence in bold). (D) By
immunoblotting, the neo-htt586 antibody detects the truncated 1-586 amino acid fragments (15
or 28 CAG) but not huntingtin truncated at amino acid 552. As a control, an N-terminal
huntingtin antibody (BKP1, right) was used to verify protein expression in extracts from these
transfected 293 cells.”27
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Figure 4. Screen for N586 IP-FCM capture/probe antibody pairs. HEK 293 cells were
transfected with either wt or mtN586. Cell lysates were used to screen potential N586 IP-FCM
capture/probe Ab pairs. Capture Abs are in rows and probe Abs in columns. Median fluorescence
intensity vs bead count is graphed. Black traces = beads alone negative control, blue traces =
wtN586, red traces = mtN586. Peaks farther to the right of the negative control peak indicate
positive detection, with greater magnitude shift indicating higher affinity.

11

Purifying N586 From Brain Lysate Digested With C6 Enzyme
Characterizing the specificity and sensitivity of the candidate N586 Ab pairs requires
purified N586 protein. To generate this, we digested forebrain lysates from Hu97/1832
humanized HD mice, which contain abundant full-length human wt and mtHTT protein, with
purified C6 enzyme. In order to isolate the cut protein of interest, microbeads were activated and
bound to IVLD N586-specific Ab. The fragment was then immpunoprecipated with the IVLD
coupled beads and eluted with glycine followed by desalting and re-suspension in PBS. Brain
lysate, C6 cut lysate, and IVLD immunoprecipated C6 cut protein were assessed by Western blot
to verify the presence of purified N586 after elution from the beads (Figure 5). Comparison of
the protein lysate and the C6 cut protein lysate lanes showed an affect from C6 cleavage, as well
as an unexpected decrease in the amount of calnexin loading control after C6 digestion, possibly
due to cleavage by the enzyme. Further analysis of the immunoprecipitation lane revealed the
presence of protein near the predicted size of N586. However, the expected two distinct bands
from wt and mtN586 were not observed.
A 10-fold dilution series of the purified protein in artificial CSF (ACSF) was generated to
determine the upper and lower limits of assay quantitation. However, N586 IP-FCM with both
IVLD/MW1 and IVLD/HD55 failed to produce a reliable signal above assay background (Figure
6), suggesting that either the antibodies weren’t recognizing the protein as expected or the
protein was not, in fact, N586.
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Figure 5. C6 cut N586 protein Western blot. Brain tissue lysate from Hu97/18 HD model mice
were digested with C6 enzyme to generate N586. Immunoprecipitation with IVLD was used to
purify the fragment. Western blotting of brain tissue lysate, C6 cut lysate, and purified N586,
with calnexin used as the loading control visualized an effect from C6 cleavage along with an
immunoprecipitated protein; however, there weren’t two distinct bands for the mt and wtN586 as
we had expected.
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Figure 6. N586 IP-FCM results with IVLD/MW1 and IVLD/HD55.
A dilution series of purified N586 was measured with ILVD/MW1 and IVLD/HD55 IP-FCM to
characterize assay sensitivity. However, no signal above assay background was detected
.
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Purification of Recombinant N586 Protein From Bacterial Expression
As an alternative approach, we attempted to purify N586 protein produced in bacteria.
Bacterial expression constructs used were pMAL-HTT1-586-Q15, expressing wtN586 with 15
glutamine repeats, and pMAL-HTT1-586-Q68, expressing mtN586 with 68 glutamine repeats.
The pMAL plasmids express the protein of interest attached to maltose-binding protein (MBP)
for isolation of recombinant protein. Plasmids were transformed into BL21(DE3) E. coli cells. A
restriction enzyme digestion verified the uptake of plasmid into the cells (Figure 7.). Inoculated
cultures were grown and induced to produce MBP-N586 with IPTG. After overnight incubation,
bacterial cells were lysed and centrifuged and the supernatant containing MBP-N586 was
collected. MBP-N586 was isolated from cell lysates through amylose resin column purification,
in which the MBP tag binds to the amylose. After washing to ensure flow through of all other
cellular contents, MBP-N586 was eluted with free maltose. Eluate was collected in 1ml fractions
and measured at A280 to find the fraction with the highest protein concentration (Table 1).
The presence of both N586 fragments were confirmed in this fraction by Western blot. A
ponceau stain of the membrane before immunoblotting showed the most prominent protein bands
in the samples at ~50 kDa, the expected size of free MBP (Figure 8). We identified N586
fragments at ~ 115 kDa and 121 kDa, representing the smaller wt and larger mtN586 fragments,
respectively, after immunoblotting using 2166 anti-HTT Ab (Figure 9), which recognizes an
epitope near the C-terminus of N586. However, MW1, which recognizes an epitope near the Nterminus of N586 was unable to recognize MBP-N586 (Figure 9), possibly due to steric
hindrance by the N-terminal MBP tag.
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Figure 7. Restriction enzyme digestion. Uncut plasmid was digested with NdeI and Not1
restriction enzymes and separated by agarose electrophoresis. Uncut plasmid served as the
control. A band near the expected molecular weight of Q15 indicated successful transformation
had occurred.
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Table 1. Purified N586-Q15 and Q68 MBP fusion protein elution fraction A280 readings
Date

Conc.

Units

260/280

A280 10mm

Sample ID
Q15_Fraction_1

3/26/18

0.1672 mg/ml

0.84

0.167

Q15_Fraction_2

3/26/18

0.05473 mg/ml

0.56

0.547

Q15_Fraction_3

3/26/18

9.55E-03 mg/ml

0.91

0.01

Q15_Fraction_4

3/26/18

-3.86E-03 mg/ml

1.86

-0.004

Q68_Fraction_1

4/2/18

0.1777 mg/ml

0.75

0.178

Q68_Fraction_2

4/2/18

1.073 mg/ml

0.53

1.073

Q68_Fraction_3

4/2/18

0.0577 mg/ml

0.57

0.058

Q68_Fraction_4

4/2/18

0.01347 mg/ml

0.013

-0.03

Bolded fractions were retained
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Figure 8. Ponceau stain of N586. A ponceau stain of nitrocellulose membrane bound to N586Q15 and 68 MBP fusion proteins shows a prominent band at the expected size of MBP, ~50 kDa,
whereas no bands were apparent at the expected size of MBP-N586-Q15 and Q68.
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Figure 9. Recombinant N586 protein Western blot. Purified N586-Q15 and Q68 recombinant
proteins were visualized by Western blot using either primary antibody (A) 2166, which verified
the presence of the MBP fusion proteins or (B) MW1, which did not detect the MBP fusion
proteins, possibly due to the MBP tag sterically hindering the antibody binding.
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CHAPTER III. DISCUSSION
Due to HTT’s inherent size, stickiness, and promiscuity, we encountered technical
challenges in generating and purifying recombinant N586. Our first approach for generating
purified N586 involved cleavage of exogenously expressed full-length human HTT transgenic
proteins in lysates of brain tissue from Hu97/18 humanized HD model mice using purified C6
enzyme, followed by purification of N586 by immunoprecipitation using the neo-epitope specific
antibody IVLD. A western blot of the brain lysate, cut lysate, and IP verified that there was an
effect of C6 cleavage in the lysate, and a protein was immunoprecipitated; however, the results
were not completely as expected, as two distinct bands for the wtHTT with Q18 and mtHTT with
Q97 were not visible. In an effort to determine if this was, indeed N586, the purified protein was
quantified and a dilution series made in ACSF. IVLD/HD55 and IVLD/MW1 IP-FCM using the
purified protein did not detect signal above background, indicating lack of antibody binding
either due to a problem with the protein or a problem with the antibody pairs. As these antibody
pairs have been previously validated, we opted to use a different method for generation of
recombinant N586.
Our second approach involved generation of recombinant N586 using bacterial
expression of MBP tagged protein. pMAL-HTT1-586-Q15 and Q68 plasmids were transformed
into BL21(DE3) E. coli. A restriction enzyme digestion was used to validate successful
transformation of plasmid into the cells. Bacterial cultures were then grown to optimum density
and induced with IPTG. Amylose resin column purification was used to isolate MBP fusion
proteins.
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During immunoblotting, a ponceau stain showed a more prominent band at the expected
size of free MBP, in comparison to those at the expected sizes of MBP-N586-Q15 and Q68. This
suggests that that free MBP is present at greater abundance than N586 in our purified sample.
Due to the N-terminal location of the polyQ tract in HTT, only 17 amino acids from the start,
HTT expression, particularly with expanded polyQ can be reduced by mRNA quality control
processes that reduce translation33, which may account for this bias toward free MBP over MBPN586.
After ponceau staining, the presence of the MBP fusion proteins was verified by Western
blot. Due to the proximity of the MW1 epitope to the N-terminal MBP tag, we also wanted to
validate binding to the recombinant fusion protein. While we did detect both recombinant
proteins showing the expected size shift between the wt and mt forms with the Ab recognizing
the C-terminus of N586, we were unable to detect MBP-N586 by Western blot using the antipolyQ Ab, suggesting that the MBP tag sterically hinders MW1 binding. To overcome this, in
ongoing work, we will cleave off the MBP tag and re-purify the protein. HTT is sticky and prone
to aggregation, thus untagged recombinant N586 is not expected to remain soluble and available
for immunoassay binding once stored. As a result, we will need to complete assay sensitivity
characterization immediately upon re-purification. This process will consist of dialysis into PBS
to remove free maltose, cleaving off the MBP tag with factor Xa protease, and amylose resin
column purification to isolate untagged N586. After cleavage of the MBP tag, we expect normal
MW1 binding to the N586 fragment, which we will concurrently verify by Western blot.
Due to the technical challenges in working with untagged N586, we will also try
alternative methods for assay specificity characterization. We will digest Hu97/18 and Hu18/18
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control littermate primary cortical neuron cell lysates with purified C6 enzyme. While we would
be unable to use these lysates for quantitative purposes as the relative amount of N586 in them
will not be known, they will allow us to determine qualitatively if an antibody pair recognizes
only mtN586 or also wtN586. Additionally, we have contacted Christopher Ross of Johns
Hopkins University who has agreed to provide us with flash frozen brain tissue from his
transgenic mtN586-82Q mouse line34. We will use these tissues to validate assay activity in brain
lysate.
If we are able to successfully characterize N586-specific IP-FCM assays, we will use
them to look for the presence of N586 in Hu97/18 humanized HD model mouse brain lysate,
CSF, and plasma and look for correlations in levels between brain and biofluids. This HD mouse
model was chosen for our studies because it expresses only human HTT, so information about
immunoassay characteristics will be more translatable as antibody affinity can vary between
species. Additionally, human mt and wtHTT are expressed at equivalent levels and total HTT
levels are equivalent to normal mouse Htt levels, thus being the closest to endogenous
conditions. Whereas if we were to use an overexpression model, we might detect N586 that
would not be present in endogenous conditions. If our assays detect N586 in Hu97/18 samples,
then we will test HD patient CSF, plasma, and brain tissue lysate to evaluate relevance to human
HD. If N586 is detected in patient CSF and/or plasma samples, N586 levels will be correlated to
clinical measures to determine if higher or lower levels of N586 are associated with disease.
The results of these studies could be used to identify new therapeutic targets for HD.
Rather than targeting C6, which may be deleterious to other biological processes that rely on its
enzymatic activity, such as ongoing apoptosis in the colon, selectively targeting the toxic
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byproduct of aa586 C6 cleavage would be more direct and likely safer. If we find that N586
persists in tissue and is likely directly toxic, then promoting N586 degradation would be a
promising therapeutic strategy. On the other hand, if N586 is rapidly degraded, suggesting that
its downstream proteolysis is toxic, stabilizing the N586 fragment may present a more promising
therapeutic strategy. All in all, the results of this study could identify new, previously unexplored
and more druggable targets for modifying aa586 C6 cleavage-induced toxicity and lead to
development of therapies that effectively and selectively inhibit this rate-limiting step in HD
pathogenesis.
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CHAPTER IV. METHODOLOGY

Primary Antibodies
MW1 was generated in Paul Patterson’s lab31 and obtained through the Developmental Studies
Hybridoma Bank (DSHB) at the University of Iowa. HD55 and IVLD were a gift from the
Michael Hayden lab35. Additional antibodies were obtained commercially, 2166 (Millipore) and
calnexin (Sigma).

Hu97/18 Brain Microdissection
Mice were anesthetized by intraperitoneal injection of 250 mg/kg Avertin and euthanized by
cervical dislocation. After decapitation with scissors, the brain was removed and placed on ice
for 1 minute to increase tissue rigidity. The hemispheres were partially divided and cortex was
peeled back to expose the inner structures. The hippocampus was extracted and placed into a prechilled tube, followed by extraction of the striatum and collection of cortex. Brain samples were
immediately snap frozen in liquid nitrogen and stored at -80oC until further use.
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Covalent-Coupling of IVLD to CML Beads
18x106 carboxylate-modified polystyrene latex (CML) beads (5 µm, Interfacial Dynamics
Corporation) were washed with 1mL of 2-(N-morpholino)ethanesulfonic acid (MES) buffer (50
mM MES pH 6.0, 1 mM Ethylenediaminetetraacetic acid (EDTA)), and microcentrifuged for 1
minute at 12,000 rpm. The beads were resuspended in 50µL of MES. To activate the beads, fresh
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride (EDAC) solution (50mg/mL in
MES) was added, and pipetted up and down continuously for 15 minutes. Beads were washed 23 times in 1mL of phosphate buffered saline (PBS). IVLD antibody (0.25 mg/mL) was added,
and allowed to gently mix for 3-4 hours at room temperature and 1400 rpm on a vortex. Beads
were washed 2-3 times with 1mL PBS and resuspended in 100 µl blocking/storage buffer (1%
bovine serum albumin (BSA) in PBS + sodium azide (NaN3)) to deactivate the beads. A
hemocytometer was used to count the beads at a 1:1000 dilution before storage at 4oC until
further use.

Purification of N586 Protein from Brain lysate
The right hemisphere of an Hu97/18 humanized HD mouse forebrain was lysed in Nonidet P40
(NP-40) lysis buffer (150 mM sodium chloride (NaCl), 50 mM Tris pH 7.4, Halt Phosphatase
and Protease inhibitors (Pierce), 10 mM sodium fluoride (NaF), 10 mM Iodoacetamide, 1%
NP40) by homogenization for 10-15s with a mechanical homogenizer followed by incubation on
ice for 20 minutes. Lysates were then sonicated for 5 seconds at 25% power and centrifuged at
14,000 rpm at 4oC for 15 minutes to pellet debris. The supernatant was transferred to

25

microcentrifuge tubes and stored at -80oC until further use. Protein quantitation was performed
with a DC assay kit (Biorad) as per the manufacturer’s instructions and absorbance read at 750
nm. A 2-fold dilution series of BSA from 20 mg/ml to 1.25 mg/ml was included to provide a
standard curve to obtain the concentration of total protein in the brain lysate.

To cut the HTT protein, 100 µg of brain lysate total protein was digested with 100u/µl purified
C6 enzyme (Enzo Life Sciences Incorporation) in 2X assay buffer (100 mM Hepes, 200 mM
NaCl, 0.2% 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPs), 2 mM
EDTA, 20% glycerol) with 200 mM Dithiothreitol (DTT) and ddH2O in a total volume of 70 µl
and incubated at 37oC for 1 hour. To immunoprecipitate N586, 0.5x105 IVLD coupled CML
latex beads were added to 50 µl C6 cut lysate and placed on a vertical rotating wheel overnight at
4oC. Beads were washed two times in 1.0 mL of ice-cold IP-FCM buffer (100 mM NaCl, 50 mM
Tris pH 7.4, 1% BSA, 0.01% NaN3) and centrifuged at 20,000g at 4oC for 3 minutes after each
wash. Beads were resuspended in 50 µl PBS. A DC assay was used to quantify the
immunoprecipitated protein as described above. To remove the protein from the Ab-coupled
beads, the sample was incubated using 3 x 50 µL of glycine (0.2 M, pH 2.6) with frequent
agitation for 10 minutes followed by gentle centrifugation at 2000 rpm for 2 minutes and
neutralization with an equal volume of Tris ph 8.0. Our protein was buffer exchanged into PBS
using a desalting spin column (Zeba) according to the manufacturer’s instructions.
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Western Blotting
Western blotting was performed to visualize cut and purified protein. Samples containing either
30 µg of brain lysate total protein, 30 µg of C6 cut brain lysate total protein, 4 µg of total IP
protein, or 1 ug of total recombinant MBP-N586 protein were combined in a total volume of 25
µl with 4 µl 6X Lithium dodecyl sulfate (LDS) loading buffer (Invitrogen), 1µl 1.0 M DTT, and
ddH2O, and heated at 90oC for 10 minutes to allow denaturation. Proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a 3-8% Tris
acetate Nupage gel (Thermofisher). Separated proteins were transferred onto a 0.45 µm
nitrocellulose membrane. To visualize all transferred proteins, the membrane was stained in 5ml
Ponceau S solution (Fisher) and placed on an orbital shaker for 5 minutes at room temperature,
then rinsed with ddH2O 2-3 times with shaking to remove the background staining.
Immunoblotting was performed using primary antibodies for the C-terminus of the N586 epitope
(MAB 2166, 1:2000), expanded polyQ (MW1, 1:500), and calnexin loading control (1:10,000).
Secondary antibodies used were IR dye 800CW goat anti-mouse (1:250, Rockland) and
AlexaFluor 680 goat anti-rabbit (1:250, Molecular probes). Proteins were visualized using the
LiCor Odyssey Imaging System.

IP-FCM of Brain Lysate
A 10-fold dilution series of purified N586 from 1.26x107 pM to 1.26x10-2 pM in a total volume
of 50 µL was generated using PBS as diluent. N586 molecular weight was estimated as the mean
of the predicted molecular weights of N586-18Q and N586-97Q, considering that the two

27

proteins should be present at equal proportions in the IP sample. Biotinylation of probe
antibodies, HD55 and MW1, was conducted using EZ-Link Sulfo-NHS-Biotin
(Thermoscientific), and free biotin was removed with buffer exchange in Amicon Ultra 3K
MWCO spin columns (Millipore). The antibody concentration was brought to 0.5 mg/ml and
stored at 4oC in PBS. Approximately 104 IVLD-coupled CML beads in 5 µl NP40 buffer were
mixed with 50 µl of brain lysate and left to immunoprecipitate overnight at 4oC with rotation to
prevent beads settling out of suspension. Beads with bound protein were washed in IP-FCM
buffer and incubated with biotinylated probe antibodies for 2 hours with rotation, followed by
another wash in IP-FCM buffer. The bound complex of bead coupled capture antibody, target
protein, and biotinylated probe antibody was then incubated for 1 hour with 1:200 StreptavidinPE fluorophore (BD Biosciences), followed by a final wash and resuspension in 200 µl of IPFCM buffer. Median fluorescence intensity (MFI) of beads was measured using an Accuri C6
flow cytometer (BD Biosciences) at a speed of 14 µl/min until approximately 3000 to 4000 total
events were counted. Bead doublets were gated out based on forward scatter area vs. forward
scatter height plots, and a singlet bead gate was defined based on forward scatter height vs. side
scatter height. All samples were run in duplicate and the average of the MFIs was scored. A
reaction containing unconjugated beads alone was used as a negative control, and this blank
value was subtracted from all experimental MFIs prior to data analysis. Prism 7 software
(GraphPad) was used to generate exponential growth nonlinear fit lines of MFI vs. log [N586].

28

Generation of Recombinant N586 Protein
BL21 DE3 cells (NEB) were transformed with pMAL-HTT1-586-Q15 or pMAL-HTT1-586Q68 plasmids according to the supplier’s instructions and grown overnight at 37oC on LB-agar
plates containing 100 µg/L ampicillin (Amp). Single Colonies were chosen from the plates and
used to inoculate 6ml of 2XYT Broth with 100 µg/L Amp, which were grown overnight in a
shaking incubator at 37oC and 245 rpm. After 16 hours, plasmid DNA was purified from 3 mL of
inoculated culture using a mini-prep kit (Qiagen) according to the manufacturer’s instructions.
The purified DNA was digested simultaneously with NdeI and Not1 restriction enzymes (NEB)
to release the N586 insert and separated using a 1.2% agarose-TBE gel to verify insert and vector
size. Once the plasmids were validated, the remaining 3 mL of inoculated culture was transferred
to 500 mL of fresh 2XYT-Amp Broth and grown until OD 600 value reached 0.6 nm as
measured using a nanodrop spectrometer. Plasmid protein expression was then induced by
adding 0.5mM IPTG (Thermoscientific) and cultures were incubated at 4oC for 16-24 hours on
an orbital shaker. This low temperature was used during N586 expression because it inhibits
aggregation of expanded polyQ proteins (Personal communication, Hailey Findlay-Black).
Cultures were centrifuged to remove media and the bacterial pellets were stored at -80oC until
use.

Purification of MBP-tagged Proteins
Bacterial cell pellets were resuspended in column buffer (Tris-HCl pH 7.4, NaCl, EDTA, and
DTT), using approximately 5 mL of buffer per gram of cells, and frozen overnight at -20oC. The
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next day, samples were thawed and sonicated three times for 30 seconds at 25% amplitude.
Samples were centrifuged at 20,000g for 20 min at 4oC to remove cellular debris and collect the
lysates. Protein purification columns were prepared by loading amylose resin slurry (20%
ethanol) into 2ml disposable polystyrene columns (Thermofisher) until there was approximately
1 mL of settled beads. The columns were washed twice with 5 volumes of column buffer.
Supernatant was loaded into the columns and allowed to flow through completely. The column
was washed with buffer until the A280 was negligible, indicating complete flow through of all
unbound proteins. Recombinant MBP-N586 proteins were eluted with 5 volumes of 10 mM
Maltose elution buffer, collecting 1ml fractions and measuring at A280 to find the fraction with
the highest protein concentration.
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